Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 20:18:1129-1142.
doi: 10.2147/TCRM.S360268. eCollection 2022.

Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic

Matthew Feldman #  1 , Sarah Marmol #  1 , Jason Margolesky  1
Affiliations
Review

Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic

Matthew Feldman et al. Ther Clin Risk Manag. .

Abstract

Parkinsonism refers to the clinical combination of bradykinesia, rigidity, tremor, and postural instability. Parkinsonism is often neurodegenerative, but it can be secondary or iatrogenic, as in drug-induced parkinsonism (DIP), which is the topic of this review. We review the pathophysiology of DIP, differentiate DIP and idiopathic Parkinson's disease (PD), list culprit medications in the development of DIP, discuss the diagnosis of DIP as well as the motor and nonmotor signs and symptoms that can help with differentiation of DIP and PD, and detail the management of DIP.

Keywords: Parkinson’s disease; drug-induced parkinsonism; neuroleptic-induced parkinsonism.

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests to declare.

References

    1. Blanchet P, Kivenko V. Drug-induced parkinsonism: diagnosis and management. Res Rev Parkinsonism. 2016;6:83–91.
    1. Shuaib UA, Rajput AH, Robinson CA, et al. Neuroleptic-induced Parkinsonism: clinicopathological study. Mov Disord. 2016;31(3):360–365. doi: 10.1002/mds.26467 - DOI - PMC - PubMed
    1. Bondon-Guiton E, Perez‐Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years’ experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26:2226–2231. doi: 10.1002/mds.23828 - DOI - PubMed
    1. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002;47(1):27–38. doi: 10.1177/070674370204700106 - DOI - PubMed
    1. Sahlholm K, Zeberg H, Nilsson J, et al. The fast-off hypothesis revisited: a functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. Eur Neuropsychopharmacol. 2016;26(3):467–476. doi: 10.1016/j.euroneuro.2016.01.001 - DOI - PubMed